TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30803886

Group type: EXPERIMENTAL
Intervention: Continuous oxygen (n=214)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Intermittent oxygen (n=145)
Number of subjects: 359
Study: 29798953

Group type: EXPERIMENTAL
Intervention: BevaciRel™ bevacizumab (study bevacizumab)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Reference bevacizumab
Number of subjects: 119
Study: 26051575

Group type: EXPERIMENTAL
Intervention: Ginger essential oil inhalation
Number of subjects: 60
Study: 23924144

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NEMEX-TJR) for 12 weeks (mean, SD 5.6)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NEMEX-TJR)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Reference group (age-matched population-based)
Number of subjects: 87
Study: 21310101

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate and benzydamine hydrochloride mouth spray (n = 72)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Penicillin plus placebo (n = 75)
Number of subjects: 147
Study: 19725009

Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (NP)
Number of subjects: 0
Study: 16955106

Group type: EXPERIMENTAL
Intervention: High-flow treatment (cyclers with high dialysate flow, no manual daytime exchange)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Manual exchange treatment (conventional APD with low nightly dialysate flow and one manual daytime exchange)
Number of subjects: 18
Study: 15727144

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/week for 8 weeks (R1)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Azithromycin 1500 mg once upon enrolment (R2)
Number of subjects: 1693

Group type: COMPARATOR
Intervention: No drugs (R3)
Number of subjects: 1693
Study: 11516807

Group type: EXPERIMENTAL
Intervention: tolterodine 1 mg bd
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg bd
Number of subjects: 251

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study: 9220215

Group type: EXPERIMENTAL
Intervention: Bromfenac (50 or 100 mg)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg/oxycodone 10 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Bromfenac (multiple doses)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Acetaminophen/oxycodone (multiple doses)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ibuprofen (multiple doses)
Number of subjects: 238
Study: 8314271

Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 10 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: sublingual captopril 25 mg
Number of subjects: 52
Study: 3321891

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31089955

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control treatment as usual
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Healthy volunteers neurofeedback training
Number of subjects: 4
Study: 30425114

Group type: EXPERIMENTAL
Intervention: IntelliVue (ECG plus Masimo pulse oximeter)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nellcor (pulse oximeter alone)
Number of subjects: 100
Study: 27412395

Group type: EXPERIMENTAL
Intervention: Brachytherapy boost (15–20 Gy over 2 days with 192Ir needle)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Electron beam therapy boost (20 Gy in 10 fractions over 2 weeks)
Number of subjects: 52
Study: 26175290

Group type: EXPERIMENTAL
Intervention: Oral health intervention (3 sessions, booklet, mobile phone text-message reminders)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 24260872

Group type: EXPERIMENTAL
Intervention: Postural restrictions after repositioning maneuvers
Number of subjects: 68

Group type: COMPARATOR
Intervention: No postural restrictions after treatment
Number of subjects: 68
Study: 21978929

Group type: EXPERIMENTAL
Intervention: salbutamol + normal saline (NS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: salbutamol + hypertonic saline (HS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: hypertonic saline (HS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: normal saline (NS)
Number of subjects: 120
Study: 18645164

Group type: EXPERIMENTAL
Intervention: IGIV-C 10% at 0.2 g/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: IGIV-C 10% at 0.4 g/kg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: IGIV-C 10% at 0.2 g/kg and 0.4 g/kg
Number of subjects: 127
Study: 17073201

Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no ozone treatment)
Number of subjects: 28
Study: 15583920

Group type: EXPERIMENTAL
Intervention: PLA/PGA bioresorbable membrane combined with Bio-Oss implantation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Collagen bioresorbable membrane combined with Bio-Oss implantation
Number of subjects: 28
Study: 11751737

Group type: EXPERIMENTAL
Intervention: Systolic pulse contour analysis
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diastolic pulse contour analysis (modified Windkessel model)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Muscular (brachial) artery compliance by cuff plethysmography
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CTTI
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Compliance-related variables
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: C(2)
Number of subjects: 91
Study: 9024012

Group type: EXPERIMENTAL
Intervention: Hands-up (HU) positioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Arms at side (AAS) positioning
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (HU and AAS)
Number of subjects: 80
Study: 8512373

Group type: EXPERIMENTAL
Intervention: Innovative educational technique using pocket-sized problem-solving cards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined groups (experimental and control)
Number of subjects: 0
Study: 3646360

Group type: EXPERIMENTAL
Intervention: High sodium intake (250 mEq/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low sodium intake (10 mEq/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute saline load during high sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water load during high sodium intake
Number of subjects: 0
Study: 30513530

Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS) for 30 minutes, 5 days per week for 2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 13
Study: 23696155

Group type: EXPERIMENTAL
Intervention: Payment card format (monthly and yearly variants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binary response filter prior to payment card follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Payment card format with filter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open-ended contingent valuation format
Number of subjects: 0
Study: 22231607

Group type: EXPERIMENTAL
Intervention: Statin medication use
Number of subjects: 153840

Group type: EXPERIMENTAL
Intervention: Statin medication use (multivariate-adjusted)
Number of subjects: 153840

Group type: EXPERIMENTAL
Intervention: Longitudinal measures of statin use
Number of subjects: 153840
Study: 19996415

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived progenitor cells (BMC)
Number of subjects: 204
Study: 18235048

Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ perindopril
Number of subjects: 19257

Group type: COMPARATOR
Intervention: Atenolol +/‐ thiazide
Number of subjects: 19257

Group type: EXPERIMENTAL
Intervention: Baseline fasting plasma glucose (FPG) >5 mmol/l
Number of subjects: 19257

Group type: EXPERIMENTAL
Intervention: Quartile of risk score
Number of subjects: 19257
Study: 16192543

Group type: EXPERIMENTAL
Intervention: Stimulating catheter (Group S); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional nonstimulating catheter (Group C); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Number of subjects: 100
Study: 12569298

Group type: EXPERIMENTAL
Intervention: Capecitabine (2500 mg/m2/day for 14 days every 21 days)
Number of subjects: 154
Study: 11352130

Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials (AEPs) obtained from two sequences of 288 stimuli of different intensities (60, 80, 90, and 110 dB SPL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: A/R measures
Number of subjects: 21
Study: 9391938

Group type: EXPERIMENTAL
Intervention: Evidence-based critiques presented at the time of ordering a KUB during Phase 1 (9-week period)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Evidence-based critiques amended to include institutional data and stronger messages about the lack of utility during Phase 2 (19-week period)
Number of subjects: 684
Study: 7806677

Group type: EXPERIMENTAL
Intervention: Supportive periodontal care with stringent plaque control (Group A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sporadic care (Group B)
Number of subjects: 23
Study: 3075474

Group type: EXPERIMENTAL
Intervention: Triple combination of CsA, azathioprine (AZA), and corticosteroids
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Prophylactic combination of CsA, corticosteroids, and antilymphocyte globulins (ALG)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: CsA dose lower than or equal to 5 mg/kg per day
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Prolonged ischemia time and grafts that did not function immediately
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: More than 1 rejection crisis
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: HLA matching, peak panel reactivity, age of the recipient, occurrence of post‐transplant renal dysfunction, and 1‐month renal function
Number of subjects: 202
Study: 30153954

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27401305

Group type: EXPERIMENTAL
Intervention: FTS pathway
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 260
Study: 24948653

Group type: COMPARATOR
Intervention: Daily pasture DM allowance of 3.5% of BW (LO)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Daily pasture DM allowance of 7.0% of BW (HI)
Number of subjects: 203
Study: 23540073

Group type: EXPERIMENTAL
Intervention: Topical preparations (novel formulations)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard (comparator) formulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated site (normal skin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated occluded site (chamber only)
Number of subjects: 10
Study: 20450622

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant transarterial chemoembolization (TACE)
Number of subjects: 2591

Group type: COMPARATOR
Intervention: Control group (resection alone)
Number of subjects: 2591
Study: 18838525

Group type: EXPERIMENTAL
Intervention: Methionine-loading (100mg/Kg body weight) with vitamins C (2g) plus E (800IU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo group (no vitamins)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 28
Study: 17243327

Group type: EXPERIMENTAL
Intervention: Mineralized cancellous bone allograft (Puros)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Anorganic bovine bone matrix (Bio-Oss)
Number of subjects: 13
Study: 12792207

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (100% oxygen for 60 minutes at 2.0 ATA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxic air (21% oxygen at 1.2 ATA)
Number of subjects: 16
Study: 11190455

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9000314

Group type: EXPERIMENTAL
Intervention: Whole-body electromagnetic coil exposure at 34 or 100 microT
Number of subjects: 1

Group type: COMPARATOR
Intervention: Sham exposures
Number of subjects: 1
Study: 1535568

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg b.i.d. for 6 months
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control
Number of subjects: 735
Study: 30118368

Group type: EXPERIMENTAL
Intervention: m‐AIP (intrathecal injection of m‐AIP, a specific antagonist of CaMKII)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: m‐AIP (postoperative treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Sham and CCI groups)
Number of subjects: 0
Study: 27470226

Group type: EXPERIMENTAL
Intervention: Culturally competent sexual health education interventions
Number of subjects: 99
Study: 25727586

Group type: EXPERIMENTAL
Intervention: Plano lens with atropine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Atropine only
Number of subjects: 73
Study: 23718905

Group type: EXPERIMENTAL
Intervention: Pharmacists' recommendations
Number of subjects: 2026
Study: 23029977

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Health coaching
Number of subjects: 13
Study: 20708966

Group type: EXPERIMENTAL
Intervention: IRIS (irinotecan plus oral S-1)
Number of subjects: 426

Group type: COMPARATOR
Intervention: FOLFIRI (folinic acid and irinotecan plus bolus and continuous infusion of fluorouracil)
Number of subjects: 426

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: IRIS
Number of subjects: 426
Study: 17996772

Group type: EXPERIMENTAL
Intervention: Closed reduction and plaster
Number of subjects: 87
Study: 15789594

Group type: EXPERIMENTAL
Intervention: Mutual Information (MI) registration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Seed-match registration
Number of subjects: 12
Study: 12470103

Group type: EXPERIMENTAL
Intervention: Total hepatic inflow clamping (group T; n = 28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Selective clamping of ipsilateral blood inflow (group H; n = 30)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups (T and H)
Number of subjects: 58
Study: 9491438

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) following personal stressful events
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Galvanic Skin Response (GSR) following personal stressful events
Number of subjects: 31

Group type: COMPARATOR
Intervention: Heart Rate (HR) for neutral statements
Number of subjects: 31

Group type: COMPARATOR
Intervention: Galvanic Skin Response (GSR) for neutral statements
Number of subjects: 31
Study: 7877303

Group type: EXPERIMENTAL
Intervention: Computerized pump perfusion
Number of subjects: 15
Study: 2194188

Group type: EXPERIMENTAL
Intervention: Picolax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Klyx enemas
Number of subjects: 0
Study: 369006

Group type: EXPERIMENTAL
Intervention: Chronic injection group (sclerotherapy with ethanolamine oleate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (conservative medical management)
Number of subjects: 31
Study: 31942704

Group type: EXPERIMENTAL
Intervention: Discrete-time hazard analysis applied to response times in visual search tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of set size effects in feature search tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory analysis of individual differences in error patterns
Number of subjects: 0
Study: 31020334

Group type: EXPERIMENTAL
Intervention: Twice-daily concurrent chemoradiation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Once-daily concurrent chemoradiation
Number of subjects: 75
Study: 28431278

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (50IU in solution)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intranasal placebo (saline)
Number of subjects: 43
Study: 25599708

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic hypoglycemia (HH) - bolus insulin 0.1 IE/kg i.v.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemia (HE) - bolus insulin 0.1 IE/kg i.v. and glucose 20% i.v. for 105 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline control (CTR)
Number of subjects: 9
Study: 23805994

Group type: EXPERIMENTAL
Intervention: Lithium (0.5 to 0.8 mEq/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 or 15 mg)
Number of subjects: 0
Study: 21831726

Group type: EXPERIMENTAL
Intervention: Liprotamase (5 capsules per day, one capsule with each meal and snack)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (1 capsule taken with meals and snacks)
Number of subjects: 138
Study: 19360520

Group type: EXPERIMENTAL
Intervention: Couple Communication Program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 16721305

Group type: EXPERIMENTAL
Intervention: Wilson frame (Union City, CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Siemens AG frame (Munich, Germany)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Andrews frame (Hollywood, CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jackson spine table (Hollywood, CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bolsters
Number of subjects: 0
Study: 15583526

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle changes, antidepressants, alpha‐2 agonists, anticonvulsants, phytoestrogens, dietary supplements
Number of subjects: 0
Study: 11744586

Group type: EXPERIMENTAL
Intervention: 3-in-1 FNB using 30 mL of ropivacaine 0.25%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3-in-1 FNB using 30 mL of ropivacaine 0.5%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3-in-1 FNB using 30 mL of bupivacaine 0.25%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 48
Study: 9378180

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in addition to usual EPI vaccines
Number of subjects: 124577

Group type: COMPARATOR
Intervention: Usual EPI vaccines (BCG, DTP, OPV, measles, yellow fever)
Number of subjects: 124577
Study: 8343610

Group type: EXPERIMENTAL
Intervention: Tolrestat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3311637

Group type: EXPERIMENTAL
Intervention: Coordinating center follow-up
Number of subjects: 0
Study: 29554017

Group type: EXPERIMENTAL
Intervention: Convergence Dialogue Meeting (CDM) added to structured physiotherapy
Number of subjects: 352

Group type: COMPARATOR
Intervention: Structured physiotherapy (Control)
Number of subjects: 352
Study: 28256051

Group type: EXPERIMENTAL
Intervention: OASIS plus standard therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard of care (SOC) therapy
Number of subjects: 7
Study: 25940537

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 24007452

Group type: EXPERIMENTAL
Intervention: mHealth based remote medication adherence measurement system (mAMS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control phase (no mAMS)
Number of subjects: 53
Study: 21168822

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine hydrochloride drops and a 4% lidocaine pledget
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine hydrochloride drops alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 4% cocaine (+ epinephrine 1/100,000) drops alone
Number of subjects: 93
Study: 18315637

Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 80

Group type: COMPARATOR
Intervention: LMAU
Number of subjects: 80
Study: 16487850

Group type: EXPERIMENTAL
Intervention: GUSTO bleeding (mild, moderate, severe)
Number of subjects: 15454

Group type: EXPERIMENTAL
Intervention: TIMI bleeding (minimal, minor, major)
Number of subjects: 15454
Study: 12620263

Group type: EXPERIMENTAL
Intervention: Left sided catheter insertion
Number of subjects: 75

Group type: COMPARATOR
Intervention: Right sided catheter insertion
Number of subjects: 75
Study: 11120525

Group type: COMPARATOR
Intervention: 125 mL intravenous fluids per hour
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 250 mL intravenous fluids per hour
Number of subjects: 195
Study: 9344298

Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS) ambulation training (30 sessions)
Number of subjects: 32
Study: 8250653

Group type: EXPERIMENTAL
Intervention: Nicotine patch (25 mg of nicotine per 24 hours for 4 weeks, then 1 patch per day for 2 weeks)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 159
Study: 3530613

Group type: EXPERIMENTAL
Intervention: Stereophotogrammetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct tracing and simple photography
Number of subjects: 0
Study: 31112512

Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/mL (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline 9 mg/mL) (n=25)
Number of subjects: 50
Study: 28268098

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 1220
Study: 26210489

Group type: EXPERIMENTAL
Intervention: Higher percentages of rTFA in plasma phospholipids (0.86 ± 0.24 %)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Concentrations of elaidic acid (a major iTFA) in plasma phospholipids
Number of subjects: 200
Study: 23724529

Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS) - 4 ml spray solution (1 ml/puff X 4) applied topically
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isotonic saline solution (0.9% NaCl) - 4 ml applied topically
Number of subjects: 40
Study: 21855745

Group type: EXPERIMENTAL
Intervention: Internet-based alcohol misuse prevention course (AlcoholEdu for College)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 2700
Study: 19548435

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus psychotherapy (Group B)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Psychotherapy alone (Group A)
Number of subjects: 47